AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16145678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow abnormality score increased
Number of subjects: 377
Study 16145678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow abnormality score did not change
Number of subjects: 377
Study 16145678 — intervention group
Group type: COMPARATOR
Intervention: Urinary CTX‐II levels in the highest tertile
Number of subjects: 377
Study 16145678 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in urinary CTX‐II levels
Number of subjects: 377
Study 16145678 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in urinary CTX‐II levels
Number of subjects: 377
Study 12198999 — intervention group
Group type: EXPERIMENTAL
Intervention: $5.00 incentive plus transportation costs
Number of subjects: 0
Study 12198999 — intervention group
Group type: COMPARATOR
Intervention: Transportation costs only (Control)
Number of subjects: 0
Study 10532133 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid diet, sennosides A and B, and a two-liter solution with PEG and electrolytes
Number of subjects: 200
Study 10532133 — intervention group
Group type: COMPARATOR
Intervention: Liquid diet plus sennosides A and B
Number of subjects: 200
Study 7768070 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml) before one oral and one intravenous dose of cyclosporine
Number of subjects: 0
Study 7768070 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclosporine (2.5 mg/kg infused for 3 hours)
Number of subjects: 0
Study 7768070 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclosporine (7.5 mg/kg)
Number of subjects: 0
Study 1691392 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI) infusion (20 ng kg‐1/min) during placebo
Number of subjects: 10
Study 1691392 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (EPI) infusion during beta 1‐selective beta‐adrenoceptor blockade with atenolol (50 mg once daily)
Number of subjects: 10
Study 1691392 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (EPI) infusion during nonselective beta‐blockade with bopindolol (1 mg once daily)
Number of subjects: 10
Study 1691392 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI) infusion during stress tests
Number of subjects: 10
Study 369646 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study 369646 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 20
Study 29804638 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/bevacizumab (Arm 1)
Number of subjects: 349
Study 29804638 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/temsirolimus (Arm 2)
Number of subjects: 349
Study 29804638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone/carboplatin/bevacizumab (Arm 3)
Number of subjects: 349
Study 29804638 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (PC Arm of trial GOG209)
Number of subjects: 349
Study 27526175 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention
Number of subjects: 231
Study 27526175 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 231
Study 25564211 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPC (4 × 5 min upper limb ischaemia)
Number of subjects: 32
Study 25564211 — intervention group
Group type: COMPARATOR
Intervention: No RIPC
Number of subjects: 32
Study 23842504 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized orders for alcohol withdrawal (AW)
Number of subjects: 175
Study 23842504 — intervention group
Group type: COMPARATOR
Intervention: Manual order writing for alcohol withdrawal (AW)
Number of subjects: 175
Study 23842504 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct clinical experience (for AW)
Number of subjects: 175
Study 23842504 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct clinical experience (for AECOPD)
Number of subjects: 175
Study 19937075 — intervention group
Group type: EXPERIMENTAL
Intervention: G1, XP Bond + Ceram-X Mono
Number of subjects: 40
Study 19937075 — intervention group
Group type: EXPERIMENTAL
Intervention: G2, P&B NT + Ceram-X Mono
Number of subjects: 40
Study 19937075 — intervention group
Group type: EXPERIMENTAL
Intervention: G3, Optibond Solo Plus + Ceram-X Mono
Number of subjects: 40
Study 19937075 — intervention group
Group type: EXPERIMENTAL
Intervention: R1, Syntac Classic + Tetric EvoCeram
Number of subjects: 40
Study 19937075 — intervention group
Group type: EXPERIMENTAL
Intervention: R2, Scotchbond 1 XT + Z250
Number of subjects: 40
Study 19164821 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person recruitment, e-mail, and community flyers
Number of subjects: 213
Study 15795147 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 12.5 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Number of subjects: 100
Study 15795147 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 25 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Number of subjects: 100
Study 15795147 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 50 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Number of subjects: 100
Study 15795147 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 100 microg added to bupivacaine 2.5 mg and fentanyl 25 microg
Number of subjects: 100
Study 15795147 — intervention group
Group type: COMPARATOR
Intervention: Control group: bupivacaine 2.5 mg and fentanyl 25 microg only
Number of subjects: 100
Study 14576732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose anthracycline regimens, four cycles given every 15 days as induction lasting for ≤6 months.
Number of subjects: 92
Study 14576732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy consolidation followed by autologous stem-cell transplantation (23 patients).
Number of subjects: 92
Study 14576732 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy regimens (69 patients).
Number of subjects: 92
Study 10868452 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric liquid bolus (280 kJ) containing paracetamol and 14C-D-xylose administered during late phase II of the intestinal MMC
Number of subjects: 8
Study 10868452 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric liquid bolus (280 kJ) containing paracetamol and 14C-D-xylose administered during phase I of the intestinal MMC
Number of subjects: 8
Study 10868452 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric liquid bolus (280 kJ)
Number of subjects: 8
Study 9010548 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning intervention
Number of subjects: 0
Study 9010548 — intervention group
Group type: COMPARATOR
Intervention: Control group (information-based health promotion programme)
Number of subjects: 0
Study 1643678 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-adjusted (pH 6.8 range 6.7-6.9) 0.75% bupivacaine with hyaluronidase
Number of subjects: 50
Study 1643678 — intervention group
Group type: COMPARATOR
Intervention: plain (pH 5.4) 0.75% bupivacaine with hyaluronidase
Number of subjects: 50
Study 6657887 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic group therapy (including autogenic training and functional relaxation)
Number of subjects: 90
Study 6657887 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 31729195 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA use (depot medroxyprogesterone acetate)
Number of subjects: 0
Study 29476687 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept on a monthly schedule
Number of subjects: 293
Study 29476687 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept on a TAE schedule
Number of subjects: 293
Study 29476687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab on a monthly schedule
Number of subjects: 293
Study 29476687 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab on a TAE schedule
Number of subjects: 293
Study 29949332 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese spinal orthopedic manipulation (TCSOM)
Number of subjects: 60
Study 29949332 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 60
Study 25265495 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mmHg low pressure group (LPG)
Number of subjects: 150
Study 25265495 — intervention group
Group type: COMPARATOR
Intervention: 12 mmHg standard pressure group (SPG)
Number of subjects: 150
Study 25265495 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mmHg high pressure group (HPG)
Number of subjects: 150
Study 22925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulceration present and positive SLN
Number of subjects: 736
Study 22925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulceration present
Number of subjects: 736
Study 22925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive SLN
Number of subjects: 736
Study 22925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Breslow thickness of ≥2.3 mm
Number of subjects: 736
Study 22925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonextremity tumor location
Number of subjects: 736
Study 22925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-SLN-positive status
Number of subjects: 736
Study 22925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulceration
Number of subjects: 736
Study 22925134 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ulceration and positive SLN
Number of subjects: 736
Study 20854235 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril plus indapamide (4 mg-1.25 mg/day)
Number of subjects: 11140
Study 18439712 — intervention group
Group type: EXPERIMENTAL
Intervention: Apples (0.63 kcal/g energy density)
Number of subjects: 49
Study 18439712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pears (0.64 kcal/g energy density)
Number of subjects: 49
Study 18439712 — intervention group
Group type: COMPARATOR
Intervention: Oat cookies (3.7 kcal/g energy density)
Number of subjects: 49
Study 15621465 — intervention group
Group type: EXPERIMENTAL
Intervention: New protocol (group 2) with oxytetracycline instilled in a fractionated-dose manner following frequent aspirations at 6h intervals
Number of subjects: 27
Study 15621465 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (group 1) with drainage until radiological evidence of lung re-expansion and then instillation of oxytetracycline
Number of subjects: 27
Study 12663723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacology group (adjusted by WBC, E-TGN, and E-MTX)
Number of subjects: 538
Study 12663723 — intervention group
Group type: COMPARATOR
Intervention: Control group (adjusted by WBC only)
Number of subjects: 538
Study 12663723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacology group
Number of subjects: 538
Study 11739065 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with sertraline
Number of subjects: 127
Study 11739065 — intervention group
Group type: COMPARATOR
Intervention: Sertraline without ERT
Number of subjects: 127
Study 9403227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg
Number of subjects: 6
Study 9403227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8234999 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg p.o. administered for 60 minutes
Number of subjects: 32
Study 8234999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3318609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin (1 g) 30 minutes before gastrostomy
Number of subjects: 107
Study 3318609 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline as a placebo
Number of subjects: 107
Study 3318609 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 107
Study 3318609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin (1 g)
Number of subjects: 107
Study 31031076 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization at 3 hours after CIED surgery (E-motion group, EMG)
Number of subjects: 200
Study 31031076 — intervention group
Group type: COMPARATOR
Intervention: Standard 24-hour immobilization (control group, CG)
Number of subjects: 200
Study 29231481 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking treatment (adhesive fabric with vaccaria seeds pressed at specific auricular points for 3 to 5 min, administered twice daily for one week)
Number of subjects: 60
Study 29231481 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar adhesive fabric at auricular points pressed for 3 to 5 min at identical time points)
Number of subjects: 60
Study 25134056 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF) intervention
Number of subjects: 234
Study 23845795 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoconcentration (≥3% absolute increase in haematocrit)
Number of subjects: 1684
Study 21483895 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-implant-supported fixed dentures (ISFDs)
Number of subjects: 20
Study 21483895 — intervention group
Group type: COMPARATOR
Intervention: Two-implant-supported overdentures (IODs)
Number of subjects: 20
Study 19160529 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 0
Study 19160529 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg/day
Number of subjects: 0
Study 16569536 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin followed by reteplase (group A)
Number of subjects: 205
Study 16569536 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin followed by abciximab and transfer to invasive center for optional PCI (group B)
Number of subjects: 205
Study 12756636 — intervention group
Group type: EXPERIMENTAL
Intervention: SMPC (special milk protein concentrate)
Number of subjects: 50
Study 12756636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10912666 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus Ursodeoxycholic acid (UDCA) (13‐15 mg/kg/day)
Number of subjects: 91
Study 10912666 — intervention group
Group type: COMPARATOR
Intervention: Interferon plus placebo
Number of subjects: 91
Study 9454431 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide in crystalline suspension (Volon A 80, 2.0 ml) intrathecally via lumbar puncture on the 5th postoperative day (group A)
Number of subjects: 160
Study 9454431 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 160
Study 9454431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups were examined again 4 weeks after discharge
Number of subjects: 160
Study 8363378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (400 mg every 12 h)
Number of subjects: 20
Study 8363378 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ofloxacin (400 mg every 12 h, 1-h infusion)
Number of subjects: 20
Study 30982556 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 7106
Study 30982556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7106
Study 29924823 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerized cognitive training (CCT) using Lumosity, 40 training sessions (5 days/week for 8 weeks)
Number of subjects: 32
Study 26829595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumina IOL
Number of subjects: 86
Study 26829595 — intervention group
Group type: COMPARATOR
Intervention: Acrysof SA60AT monofocal IOL
Number of subjects: 86
Study 24333802 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare (TC)
Number of subjects: 1189
Study 24333802 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1189
Study 22240271 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR retainers
Number of subjects: 85
Study 22240271 — intervention group
Group type: COMPARATOR
Intervention: MST retainers
Number of subjects: 85
Study 22159928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of methylcobalamin (500 mcg, 1 ml solution, three times a week for two weeks)
Number of subjects: 60
Study 22159928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ml normal saline)
Number of subjects: 60
Study 17388705 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (15-20 mg/day)
Number of subjects: 35
Study 17388705 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (15-20 mg/day) with additional blinded benztropine
Number of subjects: 35
Study 17388705 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 35
Study 15609384 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total fundoplication
Number of subjects: 107
Study 15609384 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic anterior 180 degrees fundoplication
Number of subjects: 107
Study 12141373 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-induced white finger patients
Number of subjects: 21
Study 12141373 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 10534586 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-10 scales of current pain intensity
Number of subjects: 123
Study 10534586 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-10 scales of worst pain intensity
Number of subjects: 123
Study 10534586 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-10 scales of least pain intensity
Number of subjects: 123
Study 10534586 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-10 scales of average pain intensity
Number of subjects: 123
Study 10534586 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite measures of pain intensity
Number of subjects: 123
Study 7499776 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum positive mothers' newborns
Number of subjects: 656
Study 7499776 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive newborns
Number of subjects: 656
Study 7499776 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine prophylaxis
Number of subjects: 656
Study 2081685 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 or 200 mg once a week for 4 years)
Number of subjects: 41
Study 2081685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same schedule as levamisole)
Number of subjects: 41
Study 763217 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (0.5 ml/kg/day for 14 days)
Number of subjects: 40
Study 763217 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (equivalent amounts)
Number of subjects: 40
Study 30997153 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-SZ-IFX/PF-SZ-IFX
Number of subjects: 650
Study 30997153 — intervention group
Group type: COMPARATOR
Intervention: ref-IFX/ref-IFX
Number of subjects: 650
Study 30997153 — intervention group
Group type: EXPERIMENTAL
Intervention: ref-IFX/PF-SZ-IFX
Number of subjects: 650
Study 29119239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (DEX)
Number of subjects: 259
Study 29119239 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 259
Study 26243249 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (10 mg) with bupivacaine (2 mL)
Number of subjects: 77
Study 26243249 — intervention group
Group type: COMPARATOR
Intervention: Control (bupivacaine [2 mL])
Number of subjects: 77
Study 24556807 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal attentional focus (counting coughs)
Number of subjects: 24
Study 24556807 — intervention group
Group type: COMPARATOR
Intervention: External attentional focus (counting tones)
Number of subjects: 24
Study 22146946 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone and 5 mg tropisetron (group D+T)
Number of subjects: 150
Study 22146946 — intervention group
Group type: COMPARATOR
Intervention: 8 mg dexamethasone (group D)
Number of subjects: 150
Study 22146946 — intervention group
Group type: COMPARATOR
Intervention: 5 mg tropisetron (group T)
Number of subjects: 150
Study 20875474 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenarios with information on time gap till the next meal (1 hour or 4 hours)
Number of subjects: 0
Study 20875474 — intervention group
Group type: COMPARATOR
Intervention: Scenarios without information on time gap till the next meal (1 hour or 4 hours)
Number of subjects: 0
Study 20875474 — intervention group
Group type: EXPERIMENTAL
Intervention: Products perceived as fat, high in protein, savory taste, in one piece
Number of subjects: 0
Study 17188417 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal training programme on using semiautomatic and fully automatic AEDs (15 min duration)
Number of subjects: 59
Study 15059579 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional group (arterial embolization)
Number of subjects: 38
Study 15059579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 12351298 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Axillary
Number of subjects: 100
Study 12351298 — intervention group
Group type: COMPARATOR
Intervention: Group Humeral
Number of subjects: 100
Study 9834207 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment (300 microg/m2 intravenously over 1 hour from day 1 of PBSCT)
Number of subjects: 63
Study 9834207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 63
Study 9834207 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF treatment
Number of subjects: 63
Study 9834207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 7814826 — intervention group
Group type: EXPERIMENTAL
Intervention: mCPP (0.08 mg/kg over 2 min)
Number of subjects: 12
Study 2536644 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 738
Study 1106445 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base (500 mg single dose)
Number of subjects: 10
Study 1106445 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearates (500 mg single dose)
Number of subjects: 10
Study 1106445 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolates (500 mg single dose)
Number of subjects: 10
Study 1106445 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base (250 mg every 6 hours for 4 days)
Number of subjects: 10
Study 1106445 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearates (250 mg every 6 hours for 4 days)
Number of subjects: 10
Study 31285661 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed HPV self-sampling kit
Number of subjects: 1052